food-technology-biotechnology-2018-tracks

Page 19

Notes:

allied

academies

Journal of Biotechnology and Phytochemistry| Volume: 2

October 25-26, 2018 | Frankfurt, Germany

Joint Event

Biotechnology & Medical Microbiology

World Congress on

International Conference on

Food Science & Technology

HSV and its effects in fatal primary infection in the peripartum period

Samuel Moses

East Kent Hospitals University NHS Foundation Trust, United Kingdom

erpes simplex virus infection in pregnancy can be

encountered either as a primary HSV infection or HSV

reactivation. The risk of primary HSV infection in causing

neonatal HSV that carries high neonatal morbidity/mortality

is well known. However, less frequently encountered is the

phenomenon of fatality in mothers after acquiring primary

HSV-1 in the late partum/peripartum period. Peripartum

period is a time of relative significant immunosuppression

in the mother, more specifically in regard to disturbance in

T-cell function with dysregulated immune function. 2 such

instances of fatal HSV-1 occurred in relatively healthy young

women who presented with sudden onset systemic shock

and DIC (diffuse intravascular coagulation) and liver failure

1-2 weeks after delivery by LSCS (lower segment caesarean

section). Various virological and immunological studies and the

histological features confirmed this as primary HSV-1 infection

in the mothers with florid HSV-1 viraemia, HSV hepatitis and

multi-organ failure. Data on HSV sequencing investigating

linkage between these 2 cases that occurred within 8 weeks

in a region will be presented along with literature on what,

why and how primary HSV in the early postpartum period

has been fatal to the mothers whilst sparing the neonates.

Speaker Biography

Samuel Moses is a consultant microbiologist & virologist. His clinical practice

includes infectious diseases clinic & ward consultations, infection pathology service

consultations, infection control and outpatient clinics. His interests and expertise

specifically are in sexually transmitted/blood borne infections (STI, HIV, HBV,

HCV) and transplant infections (haematopoietic stem cell transplantation, solid

organ transplantation. Samuel Moses is involved in operational and technological

advancements in the field of molecular diagnostics and in employing newer

methods in infection diagnostics and also been a member of and contributed to

legacy PHE (Public Health England) Programme Boards and to NICE technology

appraisals relating to BBV (blood borne viruses) and AMR (antimicrobial resistance).